ENMD-1198 , CAS No.864668-87-1

Item Number
E646902
Grouped product items
SKUSizeAvailabilityPrice Qty
E646902-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$500.90

Basic Description

Synonyms(13R)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthrene-3-carboxamide | ENMD-119 | DB05959 | ENMD-1198 | 2-METHOXYESTRA-1(10),2,4,16-TETRAENE-3-CARBOXAMIDE | UNII-760O4GJB9O | ESTRA-1(10),2,4,16-TETRAENE-3-CARBOXAMIDE, 2-METHOXY-
Biochemical and Physiological MechanismsENMD-1198 (IRC-110160), an orally active microtubule destabilizing agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity. ENMD-1198 is suitable for inhibiting HIF-1alpha and STAT3 in human HCC cells and leads to reduce
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
Product Description

ENMD-1198 (IRC-110160), an orally active microtubule destabilizing agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity. ENMD-1198 is suitable for inhibiting HIF-1alpha and STAT3 in human HCC cells and leads to reduced tumor growth and vascularization.

In Vitro

ENMD-1198 (0-5 μM; 24 hours) leads to a significant dose-dependent inhibition of HCC cell growth with IC 50 s of 2.5 μM for HUH-7 and HepG2 cells, respectively. ENMD-1198 (2.5 μM; 16 hours) abrogates EGF-induced phosphorylation of Akt (HUH-7), FAK (HUH-7), p44/42 MAPK (HepG2), and STAT3 (HUH-7, HepG2). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HUH-7 and HepG2 cells Concentration: 0-5 μM Incubation Time: 24 hours Result: Led to a significant dose-dependent inhibition of HCC cell growth. Western Blot AnalysisCell Line: HUH-7 and HepG2 cells Concentration: 2.5 μM Incubation Time: 16 hours Result: Abrogated EGF-induced phosphorylation of Akt (HUH-7), FAK (HUH-7), p44/42 MAPK (HepG2), and STAT3 (HUH-7, HepG2).

In Vivo

ENMD-1198 (200 mg/kg; p.o.; daily from day 7 to day 19) effectively inhibits growth of hepatocellular carcinoma through direct effects on the tumor cells, and also through inhibition of angiogenesis. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Eight-week-old male athymic nude mice (BALB/c nu/nu) (xenografted hepatocellular tumors)Dosage: 200 mg/kg Administration: P.o.; daily from day 7 to day 19 Result: Led to a significant growth inhibition of xenografted hepatocellular tumors.

Form:Solid

Associated Targets(Human)

MCF7 (126967 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HUVEC (11049 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

IUPAC Name (8S,9S,13R,14S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthrene-3-carboxamide
INCHI InChI=1S/C20H25NO2/c1-20-8-3-4-17(20)14-6-5-12-10-16(19(21)22)18(23-2)11-15(12)13(14)7-9-20/h3,8,10-11,13-14,17H,4-7,9H2,1-2H3,(H2,21,22)/t13-,14+,17-,20-/m0/s1
InChi Key YQJWOUQGXATDAE-ACNBBOPNSA-N
Canonical SMILES CC12CCC3C(C1CC=C2)CCC4=CC(=C(C=C34)OC)C(=O)N
Isomeric SMILES C[C@]12CC[C@H]3[C@H]([C@@H]1CC=C2)CCC4=CC(=C(C=C34)OC)C(=O)N
Alternate CAS 864668-87-1
PubChem CID 11483754
MeSH Entry Terms 2-methoxyoestra-1,3,5(10),16-tetraene-3-carboxamide;ENMD-1198;IRC-110160
Molecular Weight 311.42

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

Solution Calculators